417 related articles for article (PubMed ID: 19330495)
21. Cost-effectiveness of tacrolimus ointment vs. standard treatment in patients with moderate and severe atopic dermatitis: a health-economic model simulation based on a patient survey and clinical trial data.
Hjelmgren J; Svensson A; Jörgensen ET; Lindemalm-Lundstam B; Ragnarson Tennvall G
Br J Dermatol; 2007 May; 156(5):913-21. PubMed ID: 17263826
[TBL] [Abstract][Full Text] [Related]
22. Switching to sertraline or venlafaxine after failure of SSRIs treatment in major depressive disorder: an economic evaluation of the STAR*D trial.
Leelahanaj T
J Med Assoc Thai; 2012 May; 95 Suppl 5():S29-37. PubMed ID: 22934442
[TBL] [Abstract][Full Text] [Related]
23. Economics of switching to second-line antiretroviral therapy with lopinavir/ritonavir in Africa: estimates based on DART trial results and costs for Uganda and Kenya.
Simpson KN; Baran RW; Kirbach SE; Dietz B
Value Health; 2011 Dec; 14(8):1048-54. PubMed ID: 22152173
[TBL] [Abstract][Full Text] [Related]
24. The long-term outcomes of four alternative treatment strategies for primary open-angle glaucoma.
van Gestel A; Webers CA; Severens JL; Beckers HJ; Jansonius NM; Hendrikse F; Schouten JS
Acta Ophthalmol; 2012 Feb; 90(1):20-31. PubMed ID: 22289192
[TBL] [Abstract][Full Text] [Related]
25. Antidepressant treatment patterns and costs among US employees.
Birnbaum H; Greenberg PE; Tang J; Hsieh M; Wu EQ; Amand C; Ben-Hamadi R
J Med Econ; 2009 Mar; 12(1):36-45. PubMed ID: 19450063
[TBL] [Abstract][Full Text] [Related]
26. Cost-effectiveness of C-leg compared with non-microprocessor-controlled knees: a modeling approach.
Brodtkorb TH; Henriksson M; Johannesen-Munk K; Thidell F
Arch Phys Med Rehabil; 2008 Jan; 89(1):24-30. PubMed ID: 18164326
[TBL] [Abstract][Full Text] [Related]
27. Effectiveness of transcranial magnetic stimulation in clinical practice post-FDA approval in the United States: results observed with the first 100 consecutive cases of depression at an academic medical center.
Connolly KR; Helmer A; Cristancho MA; Cristancho P; O'Reardon JP
J Clin Psychiatry; 2012 Apr; 73(4):e567-73. PubMed ID: 22579164
[TBL] [Abstract][Full Text] [Related]
28. A model of the economic impact of a bipolar disorder screening program in primary care.
Menzin J; Sussman M; Tafesse E; Duczakowski C; Neumann P; Friedman M
J Clin Psychiatry; 2009 Sep; 70(9):1230-6. PubMed ID: 19689919
[TBL] [Abstract][Full Text] [Related]
29. Effectiveness and cost effectiveness of early and late prevention of HIV/AIDS progression with antiretrovirals or antibiotics in Southern African adults.
Bachmann MO
AIDS Care; 2006 Feb; 18(2):109-20. PubMed ID: 16338768
[TBL] [Abstract][Full Text] [Related]
30. Cost-effectiveness of alternative treatments for depression in low-income women.
Beil H; Beeber LS; Schwartz TA; Lewis G
J Ment Health Policy Econ; 2013 Jun; 16(2):55-65. PubMed ID: 23999203
[TBL] [Abstract][Full Text] [Related]
31. Cost-utility analysis of bevacizumab versus ranibizumab in neovascular age-related macular degeneration using a Markov model.
Patel JJ; Mendes MA; Bounthavong M; Christopher ML; Boggie D; Morreale AP
J Eval Clin Pract; 2012 Apr; 18(2):247-55. PubMed ID: 20846318
[TBL] [Abstract][Full Text] [Related]
32. The clinical and economic burden of poor adherence and persistence with osteoporosis medications in Ireland.
Hiligsmann M; McGowan B; Bennett K; Barry M; Reginster JY
Value Health; 2012; 15(5):604-12. PubMed ID: 22867768
[TBL] [Abstract][Full Text] [Related]
33. HER-2 testing and trastuzumab therapy for metastatic breast cancer: a cost-effectiveness analysis.
Elkin EB; Weinstein MC; Winer EP; Kuntz KM; Schnitt SJ; Weeks JC
J Clin Oncol; 2004 Mar; 22(5):854-63. PubMed ID: 14990641
[TBL] [Abstract][Full Text] [Related]
34. Estimating the cost-effectiveness of onabotulinumtoxinA for neurogenic detrusor overactivity in the United States.
Carlson JJ; Hansen RN; Dmochowski RR; Globe DR; Colayco DC; Sullivan SD
Clin Ther; 2013 Apr; 35(4):414-24. PubMed ID: 23522658
[TBL] [Abstract][Full Text] [Related]
35. Clinical significance of transcranial magnetic stimulation (TMS) in the treatment of pharmacoresistant depression: synthesis of recent data.
Demitrack MA; Thase ME
Psychopharmacol Bull; 2009; 42(2):5-38. PubMed ID: 19629020
[TBL] [Abstract][Full Text] [Related]
36. Cost-effectiveness of treating normal tension glaucoma.
Li EY; Tham CC; Chi SC; Lam DS
Invest Ophthalmol Vis Sci; 2013 May; 54(5):3394-9. PubMed ID: 23599342
[TBL] [Abstract][Full Text] [Related]
37. Cost effectiveness analysis comparing repetitive transcranial magnetic stimulation to antidepressant medications after a first treatment failure for major depressive disorder in newly diagnosed patients - A lifetime analysis.
Voigt J; Carpenter L; Leuchter A
PLoS One; 2017; 12(10):e0186950. PubMed ID: 29073256
[TBL] [Abstract][Full Text] [Related]
38. Cost-effectiveness of community-based treatment of severe acute malnutrition in children.
Bachmann MO
Expert Rev Pharmacoecon Outcomes Res; 2010 Oct; 10(5):605-12. PubMed ID: 20950075
[TBL] [Abstract][Full Text] [Related]
39. Cost-utility analysis of a treatment advice to discontinue inappropriate long-term antidepressant use in primary care.
Eveleigh R; Grutters J; Muskens E; Oude Voshaar R; van Weel C; Speckens A; Lucassen P
Fam Pract; 2014 Oct; 31(5):578-84. PubMed ID: 25121977
[TBL] [Abstract][Full Text] [Related]
40. Preventing pressure ulcers in long-term care: a cost-effectiveness analysis.
Pham B; Stern A; Chen W; Sander B; John-Baptiste A; Thein HH; Gomes T; Wodchis WP; Bayoumi A; Machado M; Carcone S; Krahn M
Arch Intern Med; 2011 Nov; 171(20):1839-47. PubMed ID: 21949031
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
